12:47 PM EDT, 06/13/2024 (MT Newswires) -- UroGen Pharma ( URGN ) shares jumped 41% in recent trading Thursday after the company announced an "unprecedented" 82.3% duration of response at 12 months for UGN-102, or mitomycin, to treat patients with a type of bladder cancer.

The company is evaluating UGN-102 in patients with low-grade intermediate-risk non-muscle invasive bladder cancer in a phase 3 study.

The latest data for the nonsurgical gel treatment will support a new drug application with the US Food and Drug Administration, which will be completed in Q3, the company said Thursday.

Price: 17.90, Change: +5.18, Percent Change: +40.72